Denis Migliorini, ESMO Immuno-Oncology Congress 2021: CAR T-cells for brain tumours (PART ONE)
Prof Denis Migliorini (Geneva University Hospitals, Geneva, Switzerland) to discuss his presentation at the ESMO Immuno-Oncology Congress 2021 on the challenges of developing CAR-T therapies for brain tumours, and the future of this treatment in clinical practice.
1. What are the challenges of developing CAR-T therapies for solid tumours in general, and brain tumours in particular? 00:13-03:16
2. What strategies have been proposed to enhance the efficacy of CAR-T therapies in the treatment of brain tumours? 03:16-05:14
Speaker Disclosure: Denis Migliorini has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ESMO Immuno-Oncology Congress 2021
Share this Video
Related Videos In Immuno-oncology
Tumour-selective targeted delivery of antibody-cytokine fusion proteins: Jamie Spangler, AACR 2023
Antibody-cytokine fusion proteins are a promising immunotherapy that could overcome off-target immune cell activation and the short serum half-life associated with low-dose interleukin-2 treatment. We were delighted to talk with Dr. Jamie Spangler (Johns Hopkins University, Baltimore, MD, USA) around the rationale for fusing cytokines to anti-cytokine antibodies in targeted therapy, the improved therapeutic efficacy […]
DNA damage as a target and predictor of treatment response in immunotherapy: Sandra Demaria, AACR 2023 (Part 2)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. It was a pleasure to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) to discuss how radiation-induced DNA damage is targeted in treatment strategies with immunotherapy, […]
Radiation-induced DNA damage response and tumour immunogenicity: Sandra Demaria, AACR 2023 (Part 1)
A defective DNA damage response in cancer cells can lead to genomic instability and impact the immunogenicity of tumours, improving the efficacy of immunotherapy treatment approaches. We were delighted to talk with Professor Sandra Demaria (Weill Cornell Medicine, New York, NY, USA) around the radiation-induced DNA damage response, its association with cancer and how this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!